Just how confident is Arie Belldegrun about Kite's position in the turbulent CAR-T race? He's glad you asked.
Early on in his career, Arie Belldegrun did research under Steven Rosenberg at the NCI. Now, looking back over the intervening decades, he still marvels at the first groundbreaking lab experiments that would eventually point to the late-stage CAR-T therapies at a handful of companies like Kite Pharma, where he’s the CEO now and Rosenberg is the eminent scientist in his corner of the ring.
“We were so impressed that T cells were killing cancer cells in vivo, in 1985,” Belldegrun tells me. “That’s where it started. Since then we’ve continued to work.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.